BSX · Earnings call · 2026Q3T · Full report

Strategic Initiatives

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 9 · Surprise 42

Boston Scientific entered an agreement with Blackstone Life Sciences to co-fund development of the Vitalist Circulatory Support System for cardiogenic shock. Funding will reduce R&D expense as related costs are incurred; upon milestones expected to begin in 2030, Blackstone may receive its funded amount back plus royalties on Vitalist sales. Management said the arrangement supports the program while allowing investment in other growth opportunities.

Key facts

• Boston Scientific expects launches and entry into new markets over the next few years to unlock $25 billion in new market opportunity by 2030.
• Boston Scientific added dedicated commercial resources to WATCHMAN to support concomitant and standalone procedures and referrals.